Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06267729
Registration number
NCT06267729
Ethics application status
Date submitted
5/01/2024
Date registered
20/02/2024
Date last updated
28/05/2024
Titles & IDs
Public title
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Query!
Scientific title
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO
Query!
Secondary ID [1]
0
0
D9660C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
APOLLO
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - AZD0754
Experimental: AZD0754 - AZD0754 monotherapy for treatment of participants with metastatic prostate cancer.
Other interventions: AZD0754
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.
During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.
Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs).
Query!
Assessment method [1]
0
0
Determine if treatment with AZD0754 is safe and tolerable through assessment of DLTs/DLT-like events, AEs, AESIs, SAEs, and changes from baseline in laboratory parameters, vital signs, and ECGs.
Query!
Timepoint [1]
0
0
Through study completion, an average of 2 years
Query!
Primary outcome [2]
0
0
Presence of replication-competent lentivirus (RCL) in peripheral blood samples
Query!
Assessment method [2]
0
0
Number of patients with positive RCL sample
Query!
Timepoint [2]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [1]
0
0
Prostate-specific antigen (PSA) response rate - PSA50
Query!
Assessment method [1]
0
0
PSA50 response rate is defined as the proportion of participants achieving a = 50% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later.
Query!
Timepoint [1]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [2]
0
0
PSA response rate - PSA90
Query!
Assessment method [2]
0
0
PSA90 response rate is defined as the proportion of participants achieving a = 90% decrease in PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later.
Query!
Timepoint [2]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [3]
0
0
Duration of PSA Response (DoPSA50, DoPSA90)
Query!
Assessment method [3]
0
0
Time from the date of first documented PSA50 and PSA90 until the date of documented PSA progression or death due to any cause in the absence of PSA progression.
Query!
Timepoint [3]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [4]
0
0
Durable PSA Response Rate (DRRPSA50, DRRPSA90)
Query!
Assessment method [4]
0
0
Percentage of participants who have a confirmed PSA50 and PSA90 response with a duration of at least 6 months.
Query!
Timepoint [4]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [5]
0
0
Time to PSA Response (TTPSA50, TTPSA90)
Query!
Assessment method [5]
0
0
Time from AZD0754 infusion date until the date of the first documented PSA50 and PSA90 response.
Query!
Timepoint [5]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [6]
0
0
Time to PSA Progression (TTPSAP50, TTPSAP90)
Query!
Assessment method [6]
0
0
Time from the date of first documented PSA50 and PSA90 response until the date of documented PSA progression.
Query!
Timepoint [6]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [7]
0
0
Best Overall Response (BOR)
Query!
Assessment method [7]
0
0
Best overall radiological visit response the participant achieves per RECIST V1.1 and PCWG3.
Query!
Timepoint [7]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [8]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [8]
0
0
Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR).
Query!
Timepoint [8]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [9]
0
0
Time to Response (TTR)
Query!
Assessment method [9]
0
0
Time from AZD0754 infusion date until date of first documented evidence of CR or PR.
Query!
Timepoint [9]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [10]
0
0
Duration of Response (DoR)
Query!
Assessment method [10]
0
0
Time from the date of first documented evidence of CR or PR until date of first documented disease progression or death.
Query!
Timepoint [10]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [11]
0
0
Durable Response Rate (DRR)
Query!
Assessment method [11]
0
0
Percentage of participants who have a confirmed response (CR/PR) with a duration of at least 6 months.
Query!
Timepoint [11]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [12]
0
0
Disease Control Rate (DCR)
Query!
Assessment method [12]
0
0
Percentage of participants who have a confirmed CR, PR, or Stable Disease (SD) for at least 11 and 23 weeks after AZD0754 infusion.
Query!
Timepoint [12]
0
0
12 and 24 weeks after AZD0754 infusion
Query!
Secondary outcome [13]
0
0
Percentage change in tumor size
Query!
Assessment method [13]
0
0
Percentage change in tumor size from baseline per RECIST V1.1 and PCWG3.
Query!
Timepoint [13]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [14]
0
0
Radiographic Progression-free Survival (rPFS)
Query!
Assessment method [14]
0
0
Time from AZD0754 infusion until date of objective disease progression according to RECIST V1.1 and PCWG3 criteria.
Query!
Timepoint [14]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [15]
0
0
Overall Survival (OS)
Query!
Assessment method [15]
0
0
Time from AZD0754 infusion until death due to any cause
Query!
Timepoint [15]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [16]
0
0
Time from AZD0754 Infusion to the first Symptomatic Skeletal-related Events (SSRE)
Query!
Assessment method [16]
0
0
Time from AZD0754 Infusion to the first Symptomatic Skeletal-related Event (SSRE).
Query!
Timepoint [16]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [17]
0
0
Pharmacokinetics - maximum observed serum concentration (Cmax) of AZD0754
Query!
Assessment method [17]
0
0
Maximum observed serum concentration
Query!
Timepoint [17]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [18]
0
0
Pharmacokinetics - time taken to reach maximum serum concentration (Tmax) of AZD0754
Query!
Assessment method [18]
0
0
Time taken to reach maximum serum concentration
Query!
Timepoint [18]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [19]
0
0
Pharmacokinetics - Last measurable serum concentration (Clast) of AZD0754
Query!
Assessment method [19]
0
0
Last measurable serum concentration
Query!
Timepoint [19]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [20]
0
0
Pharmacokinetics - time of last measurable serum concentration (Tlast) of AZD0754
Query!
Assessment method [20]
0
0
Time of last measurable serum concentration
Query!
Timepoint [20]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [21]
0
0
Pharmacokinetics - Exposure of AZD0754
Query!
Assessment method [21]
0
0
Area Under the concentration time curve
Query!
Timepoint [21]
0
0
Through study completion, an average of 2 years
Query!
Secondary outcome [22]
0
0
Biomarker - STEAP2 expression in Tumor
Query!
Assessment method [22]
0
0
Investigate STEAP2 expression in tumor as measured by IHC.
Query!
Timepoint [22]
0
0
Through study completion, an average of 2 years
Query!
Eligibility
Key inclusion criteria
Age
1. Participant must be 18 years or older at the time of signing the informed consent
form.
Type of Participant and Disease Characteristics
2. Participants with:
1. A histologically confirmed diagnosis of metastatic adenocarcinoma of the prostate
without known neuroendocrine differentiation or small cell features.
2. Castration-resistant prostate cancer as defined by disease progression despite
castration by orchiectomy or ongoing luteinising hormone-releasing hormone
analogue. Participants receiving medical castration therapy with gonadotropin
releasing hormone analogues should continue this treatment during the study.
3. Measurable PSA >/=1 ng/mL AND
4. Evidence of progression within 6 months prior to screening according to one of
the following:
(i) Radiographic disease progression in soft tissue based on Response Evaluation
Criteria in Solid Tumours Version 1.1 criteria with or without PSA progression as per
Prostate Cancer Working Group Criteria 3 (PCWG3) (ii) Radiographic disease progression
in bone defined as the appearance of 2 or more new bone lesions on bone scan as per
Prostate Cancer Working Group Criteria 3 (PCWG3).
3. Participant has previously received a NHA (ie, abiraterone, enzalutamide, apalutamide,
darolutamide) and taxane as part of their treatment for prostate cancer (whether
before or in the metastatic castration-resistant setting) or be ineligible for or
refuse taxanes.
4. For participants with HRR deficiency disease or breast cancer gene mutated disease,
they disease must also have received a PARP inhibitor or be intolerant of this
therapy.
5. For participants who have high microsatellite instability or deficient DNA mismatch
repair they must also have received at least one line of checkpoint inhibitors (ie,
pembrolizumab), not be eligible for, or be intolerant to therapy as per NCCN or local
treatment guidelines.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to
apheresis.
7. Minimum life expectancy of > 12 weeks prior to apheresis in the opinion of the
Investigator
8. Adequate organ and marrow function.
9. Consent and provision of tumour material to assess STEAP2 expression and other
correlative biomarkers retrospectively with pre- and post-treatment biopsies. Fresh
baseline and on-treatment biopsies are required unless these are deemed medically
unfeasible. If the participant is unable to undergo fresh biopsy, an archival tumour
sample will be required (age of biopsy cannot be greater than 10 years).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Participants with weight less than 42 kg
2. History of another primary malignancy except for malignancy treated with curative
intent with no known active disease (= 2 years) before the first dose of study
intervention and of low potential risk for recurrence. Such exceptions include
non-melanoma cancer of the skin that has undergone curative therapy or adequately
treated carcinoma in situ without evidence of disease.
3. Participants with known brain metastases.
4. Prior solid organ transplantation.
5. Active or prior documented autoimmune or inflammatory disorders (including but not
limited to inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis,
systemic lupus erythematosus, Wegener's syndrome, myasthenia gravis, Graves' disease,
rheumatoid arthritis, hypophysitis, uveitis, autoimmune pneumonitis, autoimmune
nephritis, or nephropathy, etc). The following are exceptions to this criterion:
1. Participants with vitiligo or autoimmune alopecia.
2. Participants with autoimmune hypothyroidism (eg, following Hashimoto thyroiditis)
stable on hormone replacement.
3. Any chronic inflammatory or autoimmune skin condition that does not require
systemic therapy.
4. Participants without active disease in the last 5 years may be included, but only
after consultation with the Sponsor.
5. Participants with coeliac disease controlled by diet alone.
6. Stroke, intracranial haemorrhage, or seizure within 6 months of apheresis.
7. Cardiac arrhythmias, (such as multifocal premature ventricular contractions, bigeminy,
trigeminy, ventricular tachycardia), which are symptomatic or require treatment
(Common Terminology Criteria for Adverse Events [CTCAE] Grade 3) unless controlled by
pacemaker (discussion with the Study Physician required); symptomatic or uncontrolled
atrial fibrillation despite treatment, or asymptomatic sustained ventricular
tachycardia.
8. Investigator judgement of one or more of the following:
1. Mean resting corrected QT interval > 470 ms, obtained from triplicate
electrocardiograms (ECGs) performed at screening.
2. History of QT prolongation associated with other medications that required
discontinuation of that medication, or any current concomitant medication known
to prolong the QT interval.
3. Congenital long QT syndrome, family history of long QT syndrome, or unexplained
sudden death under 40 years of age in first-degree relatives.
9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
known infection, cardiomyopathy of any aetiology, symptomatic congestive heart failure
defined by New York Heart Association class = 3), interstitial lung disease,
uncontrolled hypertension, uncontrolled diabetes mellitus, unstable angina pectoris,
history of myocardial infarction within the past 6 months prior to apheresis.
10. Active, uncontrolled epilepsy. Participants without active/uncontrolled epilepsy in
the last 5 years may be included.
11. Persistent toxicities (CTCAE Grade = 2) caused by previous anticancer therapy,
excluding alopecia. Participants with irreversible toxicity that is not reasonably
expected to be exacerbated by study intervention may be included (eg, hearing loss)
after consultation with the Study Physician or Medical Monitor. Participants with
Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with
the Study Physician or Medical Monitor.
12. Seropositive for human immunodeficiency virus (HIV).
13. Active hepatitis C infection (HCV). Participants testing positive for HCV antibody are
eligible only if the polymerase chain reaction is negative for HCV RNA.
14. Participants with hepatitis B virus (HBV) may be included under the following
circumstances:
1. Negative for hepatitis B surface antigen (HbsAg) and positive for anti-HBc
antibody
2. Positive for HbsAg, but for > 6 months have had normal transaminases and HBV DNA
levels between 0 - 2000 IU/mL (inactive carrier state) and willing to start and
maintain antiviral treatment for at least the duration of the study.
3. HBV DNA levels > 2000 IU/mL but on prophylactic antiviral treatment for the past
3 months and will maintain the antiviral treatment during the study.
15. Local requirements for the testing for infectious diseases and exclusions of
applicable participants should be followed per local regulations.
Prior/Concomitant Therapy
16. Participants may not receive full-dose long acting oral or parenteral anticoagulants
or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose from the
time of informed consent to 28-days post infusion of AZD0754. Use of short acting
direct oral anticoagulants for therapeutic and prophylactic purposes are permitted.
17. Any concomitant medications known to be associated with Torsades de Points within 14
days prior and 28 days after AZD0754 infusion.
18. Received the following:
1. Major surgery within 2 weeks prior to apheresis, or planned major surgery within
4 weeks of the study treatment administration (Note: participants with planned
surgical procedures to be conducted under local anaesthesia may participate after
discussion with the Sponsor).
2. Steroids (except inhaled steroids) or other immunomodulators (including
interleukins, interferons, and thymosins) of systemic therapeutic dose, and
systemic corticosteroids at doses exceeding 10 mg/day of prednisone or equivalent
< 7 days prior to apheresis.
19. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine
therapy targeted therapy, biologic therapy, tumour embolisation, or monoclonal
antibodies, investigational product) within 5 half-lives or = 21 days (whichever is
shorter) prior to apheresis. Radiotherapy within 14 days. However, if the radiation
portal covered = 5% of the bone marrow reserve, the participant is eligible
irrespective of the end date of radiotherapy. If sufficient washout time has not
occurred due to the schedule or PK properties of an agent, a longer washout period
will be required, as agreed by AstraZeneca and the Investigator.
20. Any concurrent anticancer treatment with the following exceptions:
1. Protocol-defined LDC
2. Hormonal therapy for non cancer-related conditions (eg, hormone replacement
therapy)
3. Androgen deprivation therapy with a luteinising-hormone replacement hormone
agonist/antagonist is required if needed to maintain testosterone level in the
castration range (levels < 50 ng/dL) and should be continued (unless bilateral
orchiectomy) throughout the trial. Following apheresis, bridging therapy is
permitted (if required) as outlined in Section 6.1.2
21. Participants should not have received any live vaccines within 30 days prior to
apheresis. Participants can receive coronavirus (COVID)-19 vaccines, at the discretion
of the Investigator, following a benefit/risk evaluation for the individual
participant and in accordance with local rules and regulations and vaccination
guidelines. Note: If a COVID-19 vaccine is administered, it should ideally be done at
least one week prior to LDC or after completion of the DLT period.
Prior/Concurrent Clinical Study Experience
22. Prior treatment with a CAR-T therapy directed at any target or any therapy that is
targeted to STEAP2.
23. Participants with a known life-threatening allergy, hypersensitivity, or intolerance
to AZD0754 or any of the excipients of the product, including dimethylsulfoxide.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/03/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
24/05/2027
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Jersey
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Pennsylvania
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of
AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06267729
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06267729
Download to PDF